Efficacy and safety of TMC278 in treatment-na?ve, HIV-1-infected patients with HBV/HCV co-infection enrolled in the phase III ECHO and THRIVE trials

M Nelson; G Amaya; N Clumeck; C Arns Da Cunha; D Jayaweera; P Junod; L Taisheng; P Tebas; M Stevens; A Buelens; S Vanveggel; K Boven

首页> 外文期刊>Journal of the International Aids Society >Efficacy and safety of TMC278 in treatment-na?ve, HIV-1-infected patients with HBV/HCV co-infection enrolled in the phase III ECHO and THRIVE trials

【24h】

Efficacy and safety of TMC278 in treatment-na?ve, HIV-1-infected patients with HBV/HCV co-infection enrolled in the phase III ECHO and THRIVE trials

机译：TMC278在治疗初治，感染HIV-1的HBV / HCV合并感染患者中的疗效和安全性纳入了ECHO和THRIVE III期试验

获取原文

获取外文期刊封面目录资料

开具论文收录证明 >>

文献代查 >>

文献数据库（团队版） >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

来源
《Journal of the International Aids Society》 |2010年第4期|共页
作者
M Nelson; G Amaya; N Clumeck; C Arns Da Cunha; D Jayaweera; P Junod; L Taisheng; P Tebas; M Stevens; A Buelens; S Vanveggel; K Boven;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类流行病学与防疫;
关键词

相似文献

外文文献
中文文献
专利

1. Pooled week 48 safety and efficacy results from the ECHO and THRIVE phase III trials comparing TMC278 vs EFV in treatment-na?ve, HIV-1-infected patients [J] . C Cohen, JM Molina, P Cahn, Journal of the International Aids Society . 2010,第Suppla4期

机译：ECHO和THRIVE III期试验汇总了第48周的安全性和有效性结果，比较了初治，感染HIV-1的患者中TMC278和EFV
2. Effect of gender and race on the week 48 findings in treatment-na?ve, HIV-1-infected patients enrolled in the randomized, phase III trials ECHO and THRIVE [J] . HodderS., ArastehK., DeWetJ., HIV medicine . 2012,第7期

机译：性别和种族对未接受过HIV-1感染的初治HIVⅢ期随机临床试验ECHO和THRIVE的第48周发现的影响
3. Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials [J] . Mark Nelson1* Gerardo Amaya2 Nathan Clumeck3 Clovis Arns da Cunha4 Dushyantha Jayaweera5 Patrice Junod6 Taisheng Li7 Pablo Tebas8 Marita Stevens9 Annemie Buelens9 Simon Vanveggel9 and Katia Boven10 on behalf of the ECHO and THRIVE Study Groups† Journal of Antimicrobial Chemotherapy . 2012,第8期

机译：III期随机，双盲ECHO和THRIVE试验纳入了rilpivirine在未经治疗且感染HIV-1的乙肝病毒/丙型肝炎病毒合并感染患者中的疗效和安全性
4. Predictability of Sustained Virological Response (SVR) in Patients with HCV/HIV Co-infection During Combination Therapy With Peginterferon Alfa-2A (40KD) (PEGASYS~R) Plus Ribavirin (COPEGUS~R) in the APRICOT Trial [C] . M. Rodriguez Torres, F.J. Torriani, E. Lissen International AIDS Conference . 2004

机译：HCV / HIV与Peginterferon Alfa-2a（40KD）（Pegasys〜R）加上利韦韦林（Copegus〜R）在杏试验期间HCV / HIV CONOMENT患者持续病毒学反应（SVR）的可预测性
5. Efficacy and safety of novel collagen conduits filled with collagen filaments to treat patients with peripheral nerve injury: A multicenter, controlled, open-label clinical trial [D] . Saeki Masaomi, 佐伯将臣 2019

机译：充满胶原细丝的新型胶原蛋白导管治疗周围神经损伤患者的疗效和安全性：一项多中心，对照，开放标签的临床试验
6. Efficacy and safety of TMC278 in treatment-naïve HIV-1-infected patients with HBV/HCV co-infection enrolled in the phase III ECHO and THRIVE trials [O] . M Nelson, G Amaya, N Clumeck, 2010

机译：在ECHO和THRIVE III期试验中TMC278在未接受过HIV-1感染的初次感染HBV / HCV合并感染的患者中的疗效和安全性
7. Efficacy and safety of TMC278 in treatment-naïve, HIV-1-infected patients with HBV/HCV co-infection enrolled in the phase III ECHO and THRIVE trials [O] . 2010

机译：在ECHO和THRIVE III期试验中，TMC278对未接受过HIV-1感染的初次感染HBV / HCV合并感染的患者的疗效和安全性

Efficacy and safety of TMC278 in treatment-na?ve, HIV-1-infected patients with HBV/HCV co-infection enrolled in the phase III ECHO and THRIVE trials

著录项

引文网络

相似文献

相关主题

期刊订阅